Immunoregulatory role of TNFα in inflammatory kidney diseases
Open Access
- 1 August 2009
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 76 (3), 262-276
- https://doi.org/10.1038/ki.2009.142
Abstract
Tumor necrosis factor alpha (TNFα), a pleiotropic cytokine, plays important inflammatory roles in renal diseases such as lupus nephritis, anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and renal allograft rejection. However, TNFα also plays critical immunoregulatory roles that are required to maintain immune homeostasis. These complex biological functions of TNFα are orchestrated by its two receptors, TNFR1 and TNFR2. For example, TNFR2 promotes leukocyte infiltration and tissue injury in an animal model of immune complex–mediated glomerulonephritis. On the other hand, TNFR1 plays an immunoregulatory function in a murine lupus model with a deficiency in this receptor that leads to more severe autoimmune symptoms. In humans, proinflammatory and immunoregulatory roles for TNFα are strikingly illustrated in patients on anti-TNFα medications: These treatments are greatly beneficial in certain inflammatory diseases such as rheumatoid arthritis but, on the other hand, are also associated with the induction of autoimmune lupus-like syndromes and enhanced autoimmunity in multiple sclerosis patients. The indication for anti-TNFα treatments in renal inflammatory diseases is still under discussion. Ongoing clinical trials may help to clarify the potential benefit of such treatments in lupus nephritis and ANCA-associated glomerulonephritis. Overall, the complex biology of TNFα is not fully understood. A greater understanding of the function of its receptors may provide a framework to understand its contrasting proinflammatory and immunoregulatory functions. This may lead the development of new, more specific anti-inflammatory drugs.Keywords
This publication has 131 references indexed in Scilit:
- TNFR1-induced NF-κB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cellsCellular Signalling, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- TNFR1‐ and TNFR2‐mediated signaling pathways in human kidney are cell type‐specific and differentially contribute to renal injuryThe FASEB Journal, 2005
- The cytokine gene polymorphisms in patients with chronic kidney graft rejectionTransplant Immunology, 2005
- Pentoxifylline suppresses renal tumour necrosis factor- and ameliorates experimental crescentic glomerulonephritis in ratsNephrology Dialysis Transplantation, 2004
- Etk/Bmx Transactivates Vascular Endothelial Growth Factor 2 and Recruits Phosphatidylinositol 3-Kinase to Mediate the Tumor Necrosis Factor-induced Angiogenic PathwayPublished by Elsevier BV ,2003
- New Indications for Treatment of Chronic Inflammation by TNF-α BlockadeThe American Journal of the Medical Sciences, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Cytokine gene polymorphisms predict acute graft rejection following renal transplantationKidney International, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999